Mon panier

IL-1 Rrp2

IL-1 Rrp2 Informations sur la molécule

Nom anglaisInterleukin-36 receptorNombre de médicaments commercialisés1
Nombre de médicaments cliniques4Alias de la cibleInterleukin-1 Receptor-Related Protein 2,Interleukin-1 Receptor-Like 2,IL-1Rrp2,Interleukin 1 Receptor Like 2,EC:3.2.2.6,IL-36R,IL1RRP2,IL-36 Receptor,IL1R-Rp2,IL1RL2,IL-1 Receptor-Related Protein 2
Phase de R&D la plus avancéeApproved
Nom anglaisInterleukin-36 receptor
Alias de la cibleInterleukin-1 Receptor-Related Protein 2,Interleukin-1 Receptor-Like 2,IL-1Rrp2,Interleukin 1 Receptor Like 2,EC:3.2.2.6,IL-36R,IL1RRP2,IL-36 Receptor,IL1R-Rp2,IL1RL2,IL-1 Receptor-Related Protein 2
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques4
Phase de R&D la plus avancéeApproved

IL-1 Rrp2 Liste de produits

  • Attribut

    Protein (5)

  • Bibliothèque de produits

    En ligne (5)

  • Espèces

    Human (4)Cynomolgus (1)

  • Étiquette

    His Tag (3)Fc Tag (1)His Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (4)Biotin-labeled (1)

IL-1 Rrp2Contexte de la molécule

The Interleukin 1 receptor family (IL-1 R) comprises at least eleven members including IL-1 RI (IL-1 R1), IL-1 RII (IL-1 R2), IL-1 RAcP (IL‑1 R3), ST2 (T1/IL-1 R4), IL-18 Ra (IL-1 Rrp/IL-1 R5), IL-1 Rrp2 (IL-1 RL2/IL-1 R6), IL-18 Rb (AcPL/IL-1 R7), IL-1RAPL‑1 (TIGIRR‑2/IL‑1 R8), and TIGIRR-1 (IL-1 R9). All family members possess three immunoglobulin (Ig)-like domains in their extracellular region. Most members also have an intracellular TIR (Toll-like receptor/IL-1 receptor signaling) domain that is also conserved in the Toll-like receptor family. Related proteins, SIGIRR (single Ig domain-containing IL-1 R-related molecule) and IL-18BP, differ from the other members by having only one Ig domain.

IL-1 Rrp2Alias de la molécule

IL-1 R6,IL-1 Rrp2,IL1RL2,IL-1RL2,IL1Rrp2,IL-1Rrp2,IL1RRP2,IL-36R

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
HB-0043HB-0043Phase 2 ClinicalHuaBo Biopharm Co LtdAcne Vulgaris; Arthritis, Rheumatoid; Autoimmune Diseases; Dermatitis, Atopic; Hidradenitis Suppurativa; Lupus Erythematosus, Systemic; Lupus Nephritis; Psoriasis; Renal Insufficiency, Chronic
Details
SHR-1139SHR1139; SHR-1139Phase 2 ClinicalGuangdong Hengrui Pharmaceutical Co LtdColitis, Ulcerative; Plaque psoriasis; Psoriasis; Pyoderma Gangrenosum
Details
TQH-2929TQH-2929; TQH2929Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupGeneralised pustular psoriasis; Psoriasis; Pustular psoriasis
Details
IMG-008IMG008Phase 1 ClinicalIkena Oncology IncAutoimmune Diseases; Inflammation
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
SpesolimabBI-655130ApprovedC.H. Boehringer Sohn Ag & Co. Kg圣利卓, SpevigoUnited StatesPsoriasisBoehringer Ingelheim Pharmaceuticals Inc2022-09-01Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Generalised pustular psoriasis; Hidradenitis Suppurativa; Netherton Syndrome; Palmoplantar pustulosis; Psoriasis; Pyoderma Gangrenosum
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques